Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 19/20 | 0.60 |
| ▸ | PDE4B | Q07343 | 16/20 | 0.60 |
| ▸ | PDE4A | P27815 | 15/20 | 0.60 |
| ▸ | PDE4C | Q08493 | 15/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14249813 | 1.00 | PDE4D (0.60) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL14249899 | 1.00 | PDE4D (0.60) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL14250216 | 1.00 | PDE4D (0.60) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL14250471 | 0.98 | PDE4D (0.57) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL14250192 | 0.98 | PDE4D (0.59) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL14249806 | 0.95 | PDE4D (0.59) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL14250174 | 0.95 | PDE4D (0.61) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL14250231 | 0.94 | PDE4D (0.56) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL14249756 | 0.94 | PDE4D (0.56) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL14249891 | 0.94 | PDE4D (0.58) | PDE4DPDE4BPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160108049-A1 | Novel Phthalazinone-Pyrrolopyrimidinecarboxamide Derivatives | ASTRAZENECA AB (SE) | 2016-04-21 | — | — | US | disclosed |
| EP-2721030-B1 | NOVEL PHTHALAZINONE-PYRROLOPYRIMIDINECARBOXAMIDE DERIVATIVES | TAKEDA GMBH (DE) | 2015-12-16 | — | — | EP | disclosed |
| US-20140112945-A1 | NOVEL PHTHALAZINONE-PYRROLOPYRIMIDINECARBOXAMIDE DERIVATIVES | TAKEDA GMBH (DE) | 2014-04-24 | — | — | US | disclosed |
| EP-2721030-A1 | NOVEL PHTHALAZINONE-PYRROLOPYRIMIDINECARBOXAMIDE DERIVATIVES | Takeda GmbH (DE) | 2014-04-23 | — | — | EP | disclosed |
| WO-2012171900-A1 | NOVEL PHTHALAZINONE-PYRROLOPYRIMIDINECARBOXAMIDE DERIVATIVES | NYCOMED GMBH (DE) | 2012-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108049-A1 | Novel Phthalazinone-Pyrrolopyrimidinecarboxamide Derivatives | PDE4A, PDE4B, PDE5A | PDE4D 5/4885PDE4B 2/4885PDE4A 1/4885 |
| US-20140112945-A1 | NOVEL PHTHALAZINONE-PYRROLOPYRIMIDINECARBOXAMIDE DERIVATIVES | PDE4A, PDE4B, PDE5A | PDE4D 5/4885PDE4B 2/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.